Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Good Sign

<< Previous

Bullboard Posts

Next >>

Comment by Arbourmarkon Jan 11, 2021 12:09pm

185 Views

Post# 32267395

RE:RE:RE:Good Sign

Hi Crow27,

I agree, there is no doubt covid-19 is having negative impact on many companies but as you pointed they are just starting to dance with various potential partners or big pharma. I am not sure exactly what people were hoping to hear short of a partnership but honestly nothing has changed in fact things are just starting to heat up;

1. Nasdaq uplisting
2. JP Morgan
3. New Hire
4. The rolling in on other patents increasing vaulation
5. The science
6. Phase 2 results
7. New opportunities
8. more options for management and board, aligns them with shareholders

I agree we would all like to read they have entered into LOI or concrete negotiations with a potential partner, but this is a process and we are only just starting. The share price has responded well, if you read through many of the posts today, you read disappointment but the share price reflects a different view.

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth